Amgen offers cash and milestones for Provention to take the lead on a celiac drug; Aveo's PhIII fails to impress, shares slide
→ Little Provention Bio has struck a deal to continue the development work on Amgen’s celiac drug, AMG 714. In exchange for taking over the mid-stage work, along with members of the Amgen team, the big biotech will pay Provention $20 million in an upcoming financing while offering a $150 million milestone on the Phase IIb. “Data presented at Digestive Disease Week 2018 from two Phase 2a clinical trials of AMG 714 demonstrated the drug’s potential in celiac disease and refractory celiac disease type II (RCD-II), an in situ gastrointestinal T cell lymphoma, and confirmed that IL-15 plays a central role in non-responsive celiac disease and RCD-II,” said Francisco Leon, co-founder and chief scientific officer of Provention.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.